OR WAIT null SECS
OptiMedica Corp. has launched its proprietary femtosecond laser platform (Catalys Precision Laser System) in the United States, with the first patient cases performed at the Mann Eye Institute and Laser Center in Houston.
Santa Clara, CA-OptiMedica Corp. has launched its proprietary femtosecond laser platform (Catalys Precision Laser System) in the United States, with the first patient cases performed at the Mann Eye Institute and Laser Center in Houston.
The platform combines a femtosecond laser, integrated 3-D optical coherence tomography imaging, and proprietary pattern scanning technology. The FDA cleared the system in December.
Mike Mann, MD, FACS, and Paul Mann, MD, are using the proprietary platform to perform laser capsulotomy and lens fragmentation during cataract surgery.
“We’ve been anxious and excited to get into laser cataract surgery since the technology first became available, but after considering all of the available competing systems, it became very clear we had to wait for [the proprietary system],” said Dr. Mike Mann. “[This system] represents the state of the art in laser cataract surgery and is the type of innovation Mann Eye patients have come to expect.”
“The U.S. launch of [this proprietary femtosecond laser platform] is a very exciting and rewarding milestone for OptiMedica, as we are now able to deliver the system’s precision and accuracy benefits to a vastly growing number of surgeons and patients around the world,” said Mark J. Forchette, OptiMedica’s president and chief executive officer.
For more articles in this issue of Ophthalmology Times eReport, click here.